Evolent Health, Inc. (EVH) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. Evolent Health, Inc. operates as a holding company with its principal asset being the Class A common units of Evolent Health LLC. The company provides specialty care management and total cost of care management solutions to health plans and risk-bearing entities. The company operates as a single reporting segment.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $444.3 million | $647.1 million | $928.0 million | $1,286.8 million |
| Operating Income (Loss) | $(1.2) million | $7.8 million | $(2.8) million | $(5.6) million |
| Net Loss (Common Shareholders) | $(51.1) million | $(6.4) million | $(123.3) million | $(31.6) million |
| Diluted EPS | $(0.44) | $(0.06) | $(1.07) | $(0.28) |
| Cash & Equivalents | $151.0 million (as of June 30, 2025) | |||
| Restricted Cash | ||||
| Total Debt (Principal) | $575.0 million (Convertible Notes) + $262.5 million (Credit Facilities) |
Note: Net loss includes significant non-cash charges related to Series A Preferred Stock accretion and extinguishment.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 31.3% in Q2 and 27.9% YTD compared to 2024. This was primarily driven by contractual updates in the Performance Suite, including a $130.4 million transition of a customer to the Specialty Technology and Services Suite and an $82.7 million narrowing of scope for certain customers.
- Cost of Revenue: Decreased 36.3% in Q2 and 32.6% YTD, largely due to lower claims costs ($210.6 million lower in Q2) resulting from the same customer transitions and scope changes. Cost of revenue as a percentage of revenue improved to 77.4% in Q2 2025 from 83.5% in Q2 2024.
- SG&A Expenses: Increased 8.7% in Q2 and 3.6% YTD, driven by higher personnel costs, partially offset by lower stock-based compensation and lease expenses.
- Unusual Items:
- Loss on Option Exercise: A one-time loss of $52.5 million was recorded in Q2 2025 related to the purchase of a joint venture interest at a price exceeding its fair value.
- Extinguishment of Series A Preferred Stock: A $9.0 million charge was recorded in Q2 2025 due to the reclassification of Series A Preferred Stock following Amendment No. 5 to the Credit Agreement.
Guidance, Outlook, and Risks
Management Commentary: Management noted that medical claims costs in the Performance Suite grew faster than historical norms in 2024 and continued to grow in early 2025, though at a slower rate. The company anticipates continued growth in treatment costs for cancer and cardiovascular patients but expects contractual protections and clinical interventions to offset these increases.
Capital Structure Updates:
- Debt Financing: The company borrowed $200 million under its Term Loan Facility in the first half of 2025. As of June 30, 2025, $200 million was outstanding under the Term Loan Facility and $62.5 million under the Revolving Facility.
- Series A Preferred Stock Exchange: On August 7, 2025 (subsequent to the reporting period), the company exchanged its Series A Preferred Stock for a new $175 million Second Lien Term Loan facility.
- 2025 Notes: The company has an Incremental Facility commitment to retire its $172.5 million 2025 Convertible Notes maturing in October 2025.
Risks and Contingencies:
- Customer Concentration: Molina Healthcare, Cook County Health, and Florida Blue Medicare represented significant portions of revenue (27.2%, 17.4%, and 14.1% respectively in Q2 2025).
- Regulatory: The "One Big Beautiful Bill Act" (OBBBA) was enacted in July 2025, amending tax laws regarding R&D and interest expense; the company is evaluating the impact.
- Liquidity: The company believes current cash and undrawn revolver facilities are sufficient for the next 12 months.
Investor Verification Checklist
- Revenue Mix Shift: Verify the long-term margin impact of transitioning customers from the Performance Suite (higher claims risk) to the Specialty Technology and Services Suite.
- Debt Maturity Wall: Confirm the execution of the refinancing or repayment plan for the $172.5 million 2025 Convertible Notes maturing in October 2025.
- Claims Cost Trends: Monitor the "Industry Climate" section for updates on medical claims cost growth rates and their impact on the Performance Suite profitability.
- Series A Exchange Impact: Review the terms of the new Second Lien Term Loan replacing the Series A Preferred Stock to understand the new interest rate obligations and covenants.
- One-Time Charges: Assess the sustainability of earnings by excluding the $52.5 million loss on option exercise and $9.0 million preferred stock extinguishment charge from future performance comparisons.